First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

S. Buti, M. Bersanelli, F. Maines, G. Facchini, F. Gelsomino, F. Zustovich, M. Santoni, E. Verri, U. De Giorgi, C. Masini, F. Morelli, M.G. Vitale, T. Sava, G. Prati, C. Librici, A.P. Fraccon, G. Fornarini, M. Maruzzo, F. Leonardi, O. Caffo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. © 2016 Elsevier Inc.
Original languageEnglish
Pages (from-to)e609-e614
JournalClinical Genitourinary Cancer
Volume15
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Renal Cell Carcinoma
Multicenter Studies
Phosphotransferases
Retrospective Studies
Clinical Trials
Neoplasms
pazopanib
sunitinib

Keywords

  • Chromophobe RCC
  • First-line treatment
  • nccRCC
  • Papillary RCC
  • Pazopanib

Cite this

First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. / Buti, S.; Bersanelli, M.; Maines, F.; Facchini, G.; Gelsomino, F.; Zustovich, F.; Santoni, M.; Verri, E.; De Giorgi, U.; Masini, C.; Morelli, F.; Vitale, M.G.; Sava, T.; Prati, G.; Librici, C.; Fraccon, A.P.; Fornarini, G.; Maruzzo, M.; Leonardi, F.; Caffo, O.

In: Clinical Genitourinary Cancer, Vol. 15, No. 4, 2017, p. e609-e614.

Research output: Contribution to journalArticle

Buti, S, Bersanelli, M, Maines, F, Facchini, G, Gelsomino, F, Zustovich, F, Santoni, M, Verri, E, De Giorgi, U, Masini, C, Morelli, F, Vitale, MG, Sava, T, Prati, G, Librici, C, Fraccon, AP, Fornarini, G, Maruzzo, M, Leonardi, F & Caffo, O 2017, 'First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study', Clinical Genitourinary Cancer, vol. 15, no. 4, pp. e609-e614. https://doi.org/10.1016/j.clgc.2016.12.024
Buti, S. ; Bersanelli, M. ; Maines, F. ; Facchini, G. ; Gelsomino, F. ; Zustovich, F. ; Santoni, M. ; Verri, E. ; De Giorgi, U. ; Masini, C. ; Morelli, F. ; Vitale, M.G. ; Sava, T. ; Prati, G. ; Librici, C. ; Fraccon, A.P. ; Fornarini, G. ; Maruzzo, M. ; Leonardi, F. ; Caffo, O. / First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. In: Clinical Genitourinary Cancer. 2017 ; Vol. 15, No. 4. pp. e609-e614.
@article{65f18a9978734b5a98e250820a316077,
title = "First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study",
abstract = "Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. {\circledC} 2016 Elsevier Inc.",
keywords = "Chromophobe RCC, First-line treatment, nccRCC, Papillary RCC, Pazopanib",
author = "S. Buti and M. Bersanelli and F. Maines and G. Facchini and F. Gelsomino and F. Zustovich and M. Santoni and E. Verri and {De Giorgi}, U. and C. Masini and F. Morelli and M.G. Vitale and T. Sava and G. Prati and C. Librici and A.P. Fraccon and G. Fornarini and M. Maruzzo and F. Leonardi and O. Caffo",
note = "Export Date: 29 August 2017 Correspondence Address: Bersanelli, M.; University Hospital of Parma, Medical Oncology, Via Gramsci 14, Italy; email: bersamel@libero.it",
year = "2017",
doi = "10.1016/j.clgc.2016.12.024",
language = "English",
volume = "15",
pages = "e609--e614",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

AU - Buti, S.

AU - Bersanelli, M.

AU - Maines, F.

AU - Facchini, G.

AU - Gelsomino, F.

AU - Zustovich, F.

AU - Santoni, M.

AU - Verri, E.

AU - De Giorgi, U.

AU - Masini, C.

AU - Morelli, F.

AU - Vitale, M.G.

AU - Sava, T.

AU - Prati, G.

AU - Librici, C.

AU - Fraccon, A.P.

AU - Fornarini, G.

AU - Maruzzo, M.

AU - Leonardi, F.

AU - Caffo, O.

N1 - Export Date: 29 August 2017 Correspondence Address: Bersanelli, M.; University Hospital of Parma, Medical Oncology, Via Gramsci 14, Italy; email: bersamel@libero.it

PY - 2017

Y1 - 2017

N2 - Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. © 2016 Elsevier Inc.

AB - Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. © 2016 Elsevier Inc.

KW - Chromophobe RCC

KW - First-line treatment

KW - nccRCC

KW - Papillary RCC

KW - Pazopanib

U2 - 10.1016/j.clgc.2016.12.024

DO - 10.1016/j.clgc.2016.12.024

M3 - Article

VL - 15

SP - e609-e614

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 4

ER -